Indications and scope of use of Cemiplimab

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor that enhances the body's immune system's recognition and attack of tumor cells by inhibiting the PD-1 (programmed cell death-1) receptor. The drug has demonstrated significant clinical efficacy in multiple tumor types, especially in the treatment of skin cancer, basal cell carcinoma and non-small cell lung cancer, and has become an important first-line treatment option.

1. Squamous cell carcinoma of the skin (CSCC):

Cimepilimab is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are unable to undergo curative surgery or definitive radiation therapy. Cutaneous squamous cell carcinoma is one of the most common skin malignancies. It has a slow course but is often associated with a higher risk of death in patients with locally advanced or metastatic disease. Cimepilimab exerts a powerful immune system effect by activating T cells, which can effectively inhibit the growth of tumors and improve the survival of patients.

2. Basal cell carcinoma (BCC):

Cimepilimab is also indicated for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC), particularly in patients who have previously received or are ineligible for hedgehog pathway inhibitor therapy. Basal cell carcinoma is one of the common types of skin cancer. Although it grows slowly, it becomes more difficult to treat when the tumor progresses to locally advanced or metastatic disease. By modulating the immune response, cimepilimab is expected to provide an effective treatment option for these refractory patients.

3. Non-small cell lung cancer (NSCLC):

For patients with non-small cell lung cancer without EGFR, ALK or ROS1 abnormalities, cimepilimab can be used in combination with platinum-based chemotherapy as a first-line treatment option. It is suitable for patients with locally advanced disease who are not suitable for surgical resection or radiotherapy and chemotherapy, or who are metastatic. In addition, cimepilimab, as monotherapy, is suitable for adult patients with non-small cell lung cancer whose tumors have high PD-L1 expression (TPS ≥ 50%). These patients are also not suitable for surgery or radiotherapy and chemotherapy, and there are no abnormalities in the EGFR, ALK or ROS1 genes.

Reference materials:https://www.libtayohcp.com/